The Clinical Efficacy of Immunomodulators in RA Patients
Recruiting
Phase 4Interventional Study
Arthritis, Rheumatoid
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Qilu Hospital of Shandong University · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
\-
1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or ACR/EULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction.
1. ACR 1987 rheumatoid arthritis classification criteria
1. morning stiffness lasting at least 1 h…
Inclusion Criteria:
\-
1.Patients with RA who meet ACR 1987 rheumatoid arthritis classification criteria or ACR/EULAR 2010 rheumatoid arthritis Classification Criteria and have knee dysfunction.
1. ACR 1987 rheumatoid arthritis classification criteria
1. morning stiffness lasting at least 1 hour (≥6w)
2. there are 3 or more joint areas swollen (≥6w)
3. swelling of the wrist, metacarpophalangeal, and proximal phalangeal joint areas (≥6w)
4. symmetrical arthrogryposis (≥6w)
5. hand x-ray changes (at least osteoporosis and joint space narrowing)
6. positive rheumatoid factor (titer \> 1:32) RA can be diagnosed by meeting 4 of the above 7 items
2. ACR/EULAR 2010 rheumatoid arthritis Classification Criteria
1. Involved joints
\- 1 large joint (0 points)
* 2-10 large joints (1 point)
* 1-3 small joints (with or without large joints) (2 points)
* 4-10 small joints (with or without large joints) (3 points)
* more than 10 small joints (at least one small joint) (5 points)
2. Serological indicators
* RF and ACPA negative (0 points)
* RF and ACPA, at least one of which is low titer positive. (2 points)
* RF and ACPA with at least one high titer positive (3 points)
3. Acute chronotropic reactants
* Both CRP and ESR normal (0 points)
* Abnormal CRP or ESR (1 point)
4. Duration of synovitis
* \<6 weeks (0 points)
* ≥6 weeks (1 point)
2.Patients with OA who meet the 1995 Classification Criteria for OA and have knee dysfunction 1995 Classification Criteria for Osteoarthritis of the Knee Clinical criteria
a. Knee pain most of the time in the last 1 month b. Bone rubbing sound c, morning stiffness ≤ 30 minutes d, age ≥ 38 years e, with bony enlargement Knee OA can be diagnosed if a+b+c+d or a+b+e is met
3.Age-sex matched healthy volunteers who checked in our hospital.
4.Age \> 18 years old;
5.Voluntarily participate in this study and sign an informed consent form
Exclusion Criteria:
1. Patients with combined active hepatitis
2. Patients with active tuberculosis
3. Patients withinfection and malignancy
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.